

VOLUME LXXVI, ISSUE 5 PART I, MAY 2023

ISSN 0043-5147

E-ISSN 2719-342X

Wiadomości Lekarskie Medical Advances



Official journal of Polish Medical Association has been published since 1928



INDEXED IN PUBMED/MEDLINE, SCOPUS, EMBASE, EBSCO, INDEX COPERNICUS,
POLISH MINISTRY OF EDUCATION AND SCIENCE, POLISH MEDICAL BIBLIOGRAPHY

VOLUME LXXVI, ISSUE 5 PART I, MAY 2023

ISSN 0043-5147
E-ISSN 2719-342X

Wiadomości Lekarskie Medical Advances



Official journal of Polish Medical Association has been published since 1928



ALUNA Publishing House



Memory of
dr Władysław
Biegański

Wiadomości Lekarskie is abstracted and indexed in: PUBMED/MEDLINE, SCOPUS, EMBASE, INDEX COPERNICUS,
POLISH MINISTRY OF EDUCATION AND SCIENCE, POLISH MEDICAL BIBLIOGRAPHY

Copyright: © ALUNA Publishing House.

Articles published on-line and available in open access are published under Creative Commons Attribution-Non Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

The journal *Wiadomości Lekarskie* is cofinanced under Contract No.RCN/SN/0714/2021/1
by the funds of the Minister of Education and Science



Wiadomości Lekarskie Medical Advances

Editor in-Chief:

Prof. Władysław Pierzchała

Deputy Editor in-Chief:

Prof. Aleksander Sieroń

Statistical Editor:

Dr Lesia Rudenko

Managing Editor:

Agnieszka Rosa – amarosa@wp.pl

International Editorial Office:

Nina Radchenko (editor)

– n.radchenko@wydawnictwo-aluna.pl

Polish Medical Association (Polskie Towarzystwo Lekarskie):

Prof. Waldemar Kostewicz – President PTL

Prof. Jerzy Woy-Wojciechowski – Honorary President PTL

International Editorial Board – in-Chief:

Marek Rudnicki

Chicago, USA

International Editorial Board – Members:

Kris Bankiewicz	San Francisco, USA	George Krol	New York, USA
Christopher Bara	Hannover, Germany	Krzysztof Łabuzek	Katowice, Poland
Krzysztof Bielecki	Warsaw, Poland	Jerzy Robert Ładny	Białystok, Poland
Zana Bumbuliene	Vilnius, Lithuania	Henryk Majchrzak	Katowice, Poland
Ryszarda Chazan	Warsaw, Poland	Ewa Małecka-Tendera	Katowice, Poland
Stanislav Czudek	Ostrava, Czech Republic	Stella Nowicki	Memphis, USA
Jacek Dubiel	Cracow, Poland	Alfred Patyk	Gottingen, Germany
Zbigniew Gasior	Katowice, Poland	Palmira Petrova	Yakutsk, Russia
Mowafaq Muhammad Ghareeb	Baghdad, Iraq	Krystyna Pierzchała	Katowice, Poland
Andrzej Gładysz	Wrocław, Poland	Waldemar Priebe	Houston, USA
Nataliya Gutorova	Kharkiv, Ukraine	Maria Siemionow	Chicago, USA
Marek Hartleb	Katowice, Poland	Vladyslav Smiiianov	Sumy, Ukraine
Roman Jaeschke	Hamilton, Canada	Tomasz Szczepański	Katowice, Poland
Andrzej Jakubowiak	Chicago, USA	Andrzej Witek	Katowice, Poland
Peter Konturek	Saalfeld, Germany	Zbigniew Wszolek	Jacksonville, USA
Jerzy Korewicki	Warsaw, Poland	Vyacheslav Zhdan	Poltava, Ukraine
Jan Kotarski	Lublin, Poland	Jan Zejda	Katowice, Poland

Distribution and Subscriptions:

Bartosz Guterman prenumerata@wydawnictwo-aluna.pl

Graphic design / production:

Grzegorz Sztank

www.red-studio.eu

Publisher:

ALUNA Publishing House

ul. Przesmyckiego 29,

05-510 Konstancin – Jeziorna

www.wydawnictwo-aluna.pl

www.wiadomoscilekarskie.pl

www.wiadlek.pl

CONTENTS

ORIGINAL ARTICLES

- Vladyslav V. Smiiianov, Svitlana M. Piven, Natalia O. Dryga, Olha I. Smiiianova, Inna O. Plakhtiienko, Natalia G. Kuchma, Kateryna I. Zhuk
 MEDICAL AND SOCIAL ANALYSIS OF PATIENTS WHO DIED OF SARS-COV-2 IN THE SPECIALIZED INFECTIOUS DEPARTMENT
 OF THE CITY OF SUMY DURING THE FIRST WAVE OF THE EPIDEMIC 891
- Włodzisław Kuliński, Emilia Gryl
 HIPPOThERAPY IN CEREBRAL PALSY – SURVEY RESEARCH 897
- Hanan Diekan Abbas, Ahmed Hassan Kudhair
 THE EFFECT OF COVID-19 INFECTION ON THE INCIDENCE OF THE RENAL ABNORMALITY FOR THE PATIENT ADMITTED
 IN TO THE COMMUNICABLE DISEASE UNITE AT AL-HAKEEM HOSPITAL 907
- Iryna R. Vyshnevskaya, Tatyana Storozhenko, Mykola P. Kopytsya, Natalia V. Bila, Andrii Kis, Mohammad Kaaki
 THE ROLE OF BIOMARKER MACROPHAGE MIGRATION INHIBITORY FACTOR IN CARDIAC REMODELING PREDICTION IN PATIENTS
 WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION 911
- Vladyslav A. Smiiianov, Leonid B. Markin, Tetiana V. Fartushok, Svitlana R. Slavitych
 EFFECTIVENESS OF THE MAGNESIUM APPLICATION IN OBSTETRICAL PRACTICE 920
- Maksym Herasymiuk, Andrii Sverstiuk, Iryna Kit
 MULTIFACTOR REGRESSION MODEL FOR PREDICTION OF CHRONIC RHINOSINUSITIS RECURRENCE 928
- Anastasiiia Efimenko, Oksana Ishchenko, Oleksii Stepanskyi, Dmytro Stepanskyi
 MICROBIOLOGICAL FEATURES OF STAPHYLOCOCCUS ASSOCIATED WITH COMPLICATIONS OF DENTAL IMPLANTATION 936
- Basma Adel Ibrahim, Sawsan Ali Hussein, Wasnaa Hadi Abdullah
 COGNITIVE FUNCTIONS IN CHILDREN WITH TYPE I DIABETES 944
- Natalya B. Gubergrits, Tetiana L. Mozhyna, Oleksii V. Tsys, Venera S. Rakhmetova
 GASTRIC AND DUODENAL AMYLOIDOSIS IN AN HIV-INFECTED PATIENT: A CASE REPORT AND A LITERATURE REVIEW 951
- Haider Abdulkareem AlMashhadani, Mustafa M. Kadhim, Saad H. Al-Badry, Nowar Gassan Ibrahim
 THE ROLE OF OXIDATIVE STRESS IN PATIENTS WITH CHRONIC KIDNEY DISEASE 960
- Valeriy Zub, Elina Manzhali
 ASSESSMENT OF QUALITY OF LIFE IN PATIENTS WITH GASTRIC CANCER IN UKRAINE 965
- Svitlana I. Chepyshko, Oleh O. Maksymiv, Mykola L. Gomon, Vitaliy I. Rozhko, Stepan V. Tkachyk, Halyna Yu. Tsymbaliuk, Larysa Ya. Fedoniuk
 RESULTS OF INFLAMMATORY AND IMMUNOLOGICAL PARAMETERS OF THE ORAL CAVITY AFTER CYSTECTOMY WITH DIFFERENT
 METHODS OF CONNECTING THE EDGES OF THE OPERATED AREA 973

Liudmyla V. Piankivska, Tetiana B. Kodlubovska, Volodymyr V. Krasnov, Larisa Yu. Babintseva RELATIONSHIP BETWEEN PROFESSIONAL MALADAPTATION OF DOCTORS – INTERNS WITH THE MEANINGFULNESS OF LIFE	981
Ahmed Khalaf Jasim, Dhiaa Jabir Aljuburi, Ali Abbar Mazael, Osamah Aldulhasan, Tamam Alaa Abdulzahra EVALUATION OF VEST-OVER-PANT TECHNIQUE IN THE TREATMENT OF POST-HYPOSPADIAS URETHROCUTANEOUS FISTULA	987
Iryna M. Nikitina, Anna A. Sinkina, Yulia B. Yakymchuk, Natalia P. Sukhostavets, Tetiana V. Kopytsia, Svitlana F. Herasymenko, Tetiana V. Babar MENSTRUAL DISORDER IN ADOLESCENTS DURING WAR	993
Viktor M. Shevchuk, Oleg L. Musiienko, Mykyta O. Sokolenko CRIMINAL OFFENCES RELATED TO ILLICIT TRAFFICKING IN FALSIFIED MEDICINES: INVESTIGATION PROBLEMS	1001
Mahmood Jawad, Karam Al-Akkam, Manar Mohammed, Saif M. Hassan ROLE OF DIMETHYL FUMARATE (NRF2 ACTIVATOR) IN REDUCING OF CIPROFLOXACIN-INDUCED HEPATOTOXICITY IN RATS VIA THE NRF2/HO-1 PATHWAY	1010
Liudmyla M. Tantsura, Olena Yu. Pylypets, Dmytro V. Tretiakov, Yevhen O. Tantsura VARIANTS OF THE FORMATION AND COURSE OF DRUG-RESISTANT EPILEPSY IN CHILDREN WITH GENETIC POLYMORPHISMS OF CYP2C9, CYP2C19, CYP3A4	1016
Saif M. Hassan, Yasmeeen Ali Hussien, Mahmood J. Jawad, Najah R. Hadi USE OF INFLIXIMAB TO ATTENUATE CEREBRAL APOPTOSIS INDUCED BY CEREBRAL ISCHEMIA/REPERFUSION IN MALE RATS	1023
Mykhailo S. Myroshnychenko, Nana M. Pasiyeshvili, Nataliia V. Kapustnyk, Volodymyr D. Markovskiy, Yuliia M. Kalashnyk-Vakulenko, Olga V. Zaytseva, Maryna A. Bondarenko, Oleksandr V. Morozov, Dmytro V. Molodan MORPHOLOGICAL ASSESSMENT OF THE LUNGS IN POST-COVID-19 SYNDROME: ANALYSIS OF AUTOPSY MATERIAL	1030
Vitalii V. Ilika, Oleksandra V. Garvasiuk, Oleksandra I. Dogolich, Batih V. Iryna THE FEATURES OF LIMITED PROTEOLYSIS IN PLACENTAL FIBRINOID IN COMBINATION WITH INFLAMMATION AND IRON DEFICIENCY ANEMIA OF PREGNANT WOMEN	1038
Vira Y. Tseluyko, Larysa M. Yakovleva, Olha V. Radchenko, Andriy V. Zhadan, Svitlana M. Sukhova, Oleksandr M. Gurov, Roman N. Askierov PECULIARITIES OF THE COURSE OF PULMONARY EMBOLISM DURING THE COVID-19 PANDEMIC	1045
Zahraa N. Fakhreldain, Hayder Ch. Assad EVALUATION THE PREVALENCE OF MULTIDRUG RESISTANCE BACTERIA AMONG IRAQI PATIENTS AND ITS ASSOCIATION WITH PATIENTS' PREDICTIVE FACTORS: A CROSS-SECTIONAL STUDY	1055
Iryna Khomenko, Oleksandra Ivakhno, Yaroslav Pershehuba, Nataliia O. Serohina TRANSFORMATION CHANGES OF PUBLIC HEALTHCARE WITHIN EPIDEMIOLOGICAL RISK MANAGEMENT LEVEL	1065

Boris Palamar, Svitlana Palamar, Tetiana Miyer, Victoria Zhelanova, Sergey Tukaiev, Hennadii Bondarenko, Natalya Holota
STUDYING ANXIETY AS A PREDICTOR IN STUDENTS TO PREDICT THE DEVELOPMENT OF BURNOUT 1070

REVIEW ARTICLES

Klaudia Ból, Aleksandra Brudzińska, Łukasz Wybrańczyk, Adam Właszczuk
EFFECT OF HORMONAL CONTRACEPTION ON DEPRESSION IN WOMEN 1078

Iryna Iakovets, Anatolii Stepanyuk, Valentyna Zverkhovska
PENITENTIARY MEDICINE IN THE CONTEXT OF NATIONAL HEALTH CARE REFORM IN UKRAINE 1084

Oleksandr A. Halushko, Olga V. Protsiuk, Oksana I. Pogorila, Maksym M. Synytsyn
HYPOGLYCEMIA IN PATIENTS WITH COVID-19: A COINCIDENCE OR A TREND? 1091

Nataliia M. Akhtyrskya, Olena Yu. Kostiuhenko
STATE REGISTRY OF HUMAN GENOMIC INFORMATION IN UKRAINE: HOW TO ACHIEVE A BALANCE BETWEEN LAW, MEDICINE
AND ETHICS 1099

Victoriia V. Haltsova, Sergiy O. Kharytonov, Andrii M. Iashchenko
HARM TO LIFE AND HEALTH AS A RESULT OF ACTS OF ILLEGAL ADOPTION: CRIMINAL LEGAL AND MEDICO-PSYCHOLOGICAL ASPECTS 1106

Iryna Iakovets, Olena Haltsova, Oksana Kashyntseva
ENSURING THE RIGHT TO HEALTH CARE FOR GROUPS VULNERABLE TO HIV IN PENITENTIARY INSTITUTIONS
AND PRE-TRIAL DETENTION CENTERS IN UKRAINE 1113

Larysa Grynko, Hennadii Chornyi, Maryna Kostenko
SALE OF FALSIFIED MEDICINES VIA THE INTERNET IN UKRAINE: PROBLEMS OF DETECTION AND COUNTERACTION 1122

Halyna V. Bilavych, Natalia V. Sultanova, Iryna S. Litvinenko, Jan V. Biławicz, Nadiya O. Fedchyshyn, Larysa Ya. Fedoniuk, Borys P. Savchuk
ANTI-ALCOHOL EDUCATION OF CHILDREN, YOUTH AND ADULTS AS A FACTOR IN THE FORMATION OF HEALTH-SAVING
COMPETENCE THROUGH THE PRISM OF THE HISTORICAL EXPERIENCE OF UKRAINE 1129

LETTER TO EDITOR

Julia Maya Nowak
A NEW OUTLOOK ON PATIENT CARE – MY EXPERIENCE AT MAYO CLINIC AS AN INTERNATIONAL MEDICAL STUDENT 1137

ORIGINAL ARTICLE

MORPHOLOGICAL ASSESSMENT OF THE LUNGS IN POST-COVID-19 SYNDROME: ANALYSIS OF AUTOPSY MATERIAL

DOI: 10.36740/WLek202305120

Mykhailo S. Myroshnychenko¹, Nana M. Pasiyeshvili², Nataliia V. Kapustnyk², Volodymyr D. Markovskiy¹, Yuliia M. Kalashnyk-Vakulenko¹, Olga V. Zaytseva¹, Maryna A. Bondarenko¹, Oleksandr V. Morozov¹, Dmytro V. Molodan¹

¹ KHARKIV NATIONAL MEDICAL UNIVERSITY, KHARKIV, UKRAINE

² PUBLIC NONPROFIT ORGANIZATION OF THE KHARKIV DISTRICT COUNCIL «REGIONAL CLINICAL PERINATAL CENTRE», KHARKIV, UKRAINE

ABSTRACT

The aim was to reveal the morphological features of the lungs in post-COVID-19 syndrome.

Materials and methods: The material of the study was autopsy material – fragments of the lung tissue from 96 deceased (59 men and 37 women). During the lifetime, all patients had in anamnesis COVID-19 of varying severity, and after the treatment of this infection, they had various manifestations of respiratory failure until death. The average duration of the post-COVID-19 period was 148.6±9.5 days. Based on the severity of COVID-19 in anamnesis, all cases were divided into three groups. Group 1 included 39 cases with mild COVID-19 in anamnesis. Group 2 included 24 cases with moderate severity of COVID-19 in anamnesis. Group 3 included 33 cases with severe COVID-19 in anamnesis. Histological, histochemical, morphometric and statistical research methods were used.

Results: Morphological features of the lungs in post-COVID-19 syndrome were the presence of pneumosclerosis; focal-diffuse immune cells infiltration; emphysematous and atelectatic changes; degenerative-desquamatic changes in the alveolar epithelium; metaplastic changes of connective tissue; dystrophic calcification; dystrophic, metaplastic and dysplastic changes in the epithelial layer of bronchial tree; hemodynamic disorders. Pneumosclerosis, focal-diffuse immune cells infiltration, alternative changes in the alveolar epithelium, emphysematous and atelectatic changes, hemodynamic disorders increased with an increase the severity of COVID-19. Metaplastic changes of connective tissue, dystrophic calcification, dystrophic, metaplastic and dysplastic changes in epithelial layer of bronchial tree did not depend on the severity of the infection.

Conclusions: The changes identified by the authors help to explain pulmonary manifestations of post-COVID-19 syndrome. They should be the basis for the oncological alertness formation among doctors, the development of rehabilitation and treatment measures for such category of patients.

KEY WORDS: lungs, morphology, autopsy, post-COVID-19 syndrome

Wiad Lek. 2023;76(5 p.1):1030-1037

INTRODUCTION

After the COVID-19 pandemic, doctors of many specialties are now faced with a major global concern – post-COVID-19 syndrome [1]. The post-COVID-19 syndrome, according to some scientists, is the hidden part of a metaphorical iceberg that requires immediate interdisciplinary research [2].

Post-COVID-19 syndrome, according to the World Health Organization, includes symptoms and abnormalities persisting or present beyond 12 weeks of the onset of SARS-CoV-2 infection, lasting for at least 2 months and not attributable to alternative diagnoses [3]. Post-COVID-19 syndrome has an official disease status in the International Classification of Diseases (10th revision), where it is designated as a «post-COVID-19 condition» under the code U09.9 [4]. The impact of post-COVID-19 syndrome is enormous for patients, the healthcare system and economic development [5].

The prevalence of post-COVID-19 syndrome has varied across and within many countries: UK – 1.6-71%, Germany – 35-77%, China 49-76%, Africa – 68%, India –22%, Bangladesh – 16-46%, Denmark – 1%, Italy – 5-51%, USA – 16-53%, Norway – 61% [6].

The mechanism of the post-COVID syndrome is a debatable and not fully understood issue. Post-COVID-19 syndrome, according to many scientists, is a complex and multifactorial syndrome involving aberrant immune responses, virus-specific pathophysiological alterations, inflammatory damage in response to the acute infection and mechanisms of viral persistence in certain tissues, SARS-CoV-2 interactions with host microbiome/virome communities, clotting/coagulation issues and dysfunctional brainstem/vagus nerve signaling [7, 8].

Post-COVID-19 symptoms vary in intensity and duration and are not linear or sequential [9]. Post-COVID-19 syndrome may manifest by neurological, respiratory, car-

Table I. Pathological anatomy diagnoses and causes of death in the studied cases.

Pathological anatomy diagnosis	Cause of death	Number of cases	
		Absolute	Relative (%)
Myocardial infarction	Acute cardiac insufficiency	39	40.6
Atherosclerotic cardiosclerosis	Chronic cardiac /cardiopulmonary insufficiency	34	35.4
Cerebral infarction	Dislocation of the brain stem	12	12.5
Deep vein thrombophlebitis of the lower extremities	Thromboembolism of the pulmonary artery	7	7.3
Gangrene of the intestine	Intoxication	4	4.2

diovascular, hematologic, gastrointestinal and other symptoms, but the most common are respiratory disorders [1, 10]. Respiratory disorders include external respiration dysfunction, dyspnea, cough, reduced exercise tolerance, post-COVID-19 interstitial lung disease, pain in the intercostal space, pulmonary hypertension, etc. [1, 11, 12].

In the available literature, we did not find comprehensive morphological studies aimed at identifying the morphofunctional state of the lungs in patients with post-COVID-19 syndrome, which would make it possible to understand the morphological substrate of clinically observed signs of respiratory disorders in this category of patients.

THE AIM

The purpose was to reveal the morphological features of the lungs in post-COVID-19 syndrome.

MATERIALS AND METHODS

The material of the study was autopsy material – fragments of the lung tissue from 96 deceased (59 men and 37 women). Autopsies were performed on the basis of pathoanatomical department of Public nonprofit organization of the Kharkiv District Council «Regional Clinical Hospital» (Ukraine). During the lifetime, all patients had in anamnesis COVID-19 of varying severity, and after the treatment of this infection, they had various manifestations of respiratory failure until death. The average duration of the post-COVID-19 period was 148.6 ± 9.5 days. In all cases, it was found the presence of immunoglobulin G antibodies to SARS-CoV-2 in diagnostic titers.

Based on the severity of COVID-19 in anamnesis, all cases were divided into three groups. Group 1 included 39 cases with mild COVID-19 in anamnesis. Group 2 included 24 cases with moderate severity of COVID-19 in anamnesis. Group 3 included 33 cases with severe COVID-19 in anamnesis.

An analysis of the causes of death and pathological anatomy diagnoses is given in Table I. In most cases the cause of death was acute cardiac or chronic cardiac /cardiopulmonary insufficiency.

Autopsy material was fixed in a 10% solution of neutral buffered formalin according to the generally accepted technique and embedded in paraffin. Serial sections of 3-4 μm thick were made from paraffin blocks. The slides were stained with hematoxylin and eosin, picrofuchsin according to van Gieson, according to Mallory. The slides were studied using an Olympus BX-41 microscope. A morphometric study was carried out using the Olympus DP-soft version 3.1 software.

The obtained digital data were statistically processed, using the Statistica 10.0 program. The average indicators in the groups were compared, using the nonparametric Mann-Whitney U test. Differences were considered significant at $p < 0.05$.

RESULTS

Survey microscopy of the slides in all cases revealed pneumosclerosis, characterized by the excessive growth of connective tissue fibers perivascular and directly in the vessels walls of various calibers, around the bronchi and bronchioles or directly in their walls, in the interalveolar septa with its thickening, in the alveoli lumen (Fig. 1).

The results of a morphometric study also indicated sclerotic changes in the lungs. In all groups, in the lungs during morphometric study, the specific volume of the parenchyma, including the system of the bronchial tree and the system of the acini, and the stroma, represented by connective tissue fibers with vessels located between them, were determined (Fig. 2). In the direction from group 1 to group 3, the specific volume of the parenchyma decreased ($p < 0.05$), and the specific volume of the stroma increased ($p < 0.05$). These changes indicated an increase of pneumosclerosis with an increase of the infection severity.

Among the connective tissue fibers during Mallory staining a decrease in the number of elastic fibers and an increase in the number of collagen fibers in the direction from group 1 to group 3 were revealed, which also indicated about the sclerotic changes. In group 3, in a significant number of fields of vision, elastic fibers were practically not detected.




Fig. 1. Sclerotic changes in the lungs in groups 1 (a) and 3 (b). Immune cells infiltration in foci of pneumosclerosis. Stained with hematoxylin and eosin, a) $\times 200$, b) $\times 100$.




Fig. 2. The average values of the specific volumes of parenchyma and stroma in the lungs in groups 1-3.

In the foci of pneumosclerosis in all groups, focal-diffuse infiltration by immune cells was noted, which increased in the direction from group 1 to group 3 (Fig. 1).

Also, in the areas of pneumosclerosis, metaplastic changes of the connective tissue were detected, characterized by the presence of hyaline cartilage (Fig. 3), bone and adipose tissues (Fig. 4). These changes were identified in group 1 in 8 cases (20.5%), in group 2 – in 6 cases (25%), in group 3 – in 9 cases (27.3%). Comparative analysis did not reveal significant ($p > 0.05$) differences between the numbers of cases with this microscopic finding in all groups.

Against the background of the changes described above in the areas of pneumosclerosis, foci with dystrophic calcification were also detected in group 1 in 7 cases (17.9%), in group 2 – in 4 cases (16.7%), in group 3 – in 6 cases (18.2%) (Fig. 5). The severity of dystrophic calcification did not depend on the severity of the infection.

In the deformed bronchial tree, due to sclerotic

changes, we noted various general pathological processes in the epithelial layer. In all cases of groups 1-3, dystrophic changes in the epithelium were determined. Also in the epithelial layer in 8 cases (20.5%) of group 1, in 5 cases (20.8%) of group 2 and in 7 cases (21.2%) of group 3 metaplastic and dysplastic changes sometimes with the formation of adenomatous structures were detected (Fig. 6). The severity of the identified changes in the epithelium of the bronchial tree did not depend on the severity of COVID-19.

Microscopic examination of the lungs in all groups revealed focal degenerative-desquamatic changes in the alveolar epithelium, as well as unchanged alveoli, alveoli with emphysematous and atelectatic changes (Fig. 7). Alterative changes in the alveolar epithelium increased with an increase the severity of COVID-19. Morphometry identified that with an increase of the COVID-19 severity, the specific volume of unchanged alveoli (group 1 – $72.5 \pm 1.54\%$, group 2 – $60.9 \pm 2.11\%$,




Fig. 3. Hyaline cartilage in the area of pneumosclerosis. Stained with hematoxylin and eosin, $\times 400$.




Fig. 4. Adipose tissue in the area of pneumosclerosis. Stained with hematoxylin and eosin, $\times 100$.




Fig. 5. Dystrophic calcification in the area of pneumosclerosis. Stained with hematoxylin and eosin, $\times 100$.




Fig. 6. Metaplastic and dysplastic changes in the epithelial layer of the bronchial tree in group 3. Stained with hematoxylin and eosin, $\times 400$.

group 3 – $(51.8 \pm 2.43)\%$) decreased ($p < 0.05$), and the specific volume of emphysematous and atelectatically changed alveoli taken together (group 1 – $(27.5 \pm 1.54)\%$, group 2 – $(39.1 \pm 2.11)\%$, group 3 – $(48.2 \pm 2.43)\%$) increased ($p < 0.05$) (Fig. 8).

In all cases of groups 1-3, against the background of the described changes, we detected hemodynamic disorders that increased in the direction from group 1 to group 3 and were characterized by edema, vascular plethora, thrombosis, small-focal hemorrhages with hemosiderin deposition (Fig. 9).

DISCUSSION

The authors for the first time on autopsy material carried out a comprehensive morphological study of the lungs in post-COVID-19 syndrome, which makes it possible to explain the respiratory manifestation of this syndrome.

This study revealed morphological changes in the parenchyma and stroma of the lungs in post-COVID-19 syndrome. Some preliminary results of this study were published by the authors earlier [13]. In this article, the authors publish the final results of the study.

The pneumosclerosis identified by the authors is the outcome of COVID-19, which has also been noted by many scientists [14]. Such pathological process is characterized by the replacement of parenchymal elements with connective tissue, the substitution of elastic fibers with collagen fibers, followed by a decrease in lung compliance, compression of the bronchial tree, which leads to the development of ventilation and parenchymal respiratory failure resulting in decreased quality of life, increased morbidity and mortality [15]. The authors noted an increase of pneumosclerosis with an increase the severity of the infection.

Sclerosis from the point of view of the reversibility of




Fig. 7. Emphysematous and atelectatic changes in lung tissue in group 2. Stained with hematoxylin and eosin, $\times 100$.

the process can be reversible (labile), partially reversible (stable), irreversible (progressive). In our study, among the connective tissue fibers, a decrease in the number of elastic fibers and their complete disappearance, an increase in the number of collagen fibers were revealed, which, from our point of view, indicates the irreversibility of the sclerotic process in such category of patients.

The pathogenesis of pulmonary fibrosis in post-COVID-19 period is a complex and not fully understood issue [15]. Most scientists associate the development of pneumosclerosis after COVID-19 with transforming growth factor beta (TGF- β), which is a multifunctional cytokine with profibrogenic, antiinflammatory and immunosuppressive effects that are elevated after COVID-19 [2].

Interestingly, one of the factors contributing to the development of pneumosclerosis is mechanical ventilation, which was used in the treatment of respiratory

distress syndrome. Due to mechanical ventilation shear forces not only induce secretion of TGF- β but also activate collagen synthesis and inhibit collagenase production [2].

Some scientists assign the leading role in the development of pneumosclerosis after COVID-19 to endothelial-mesenchymal and epithelial-mesenchymal transformation. In the development of the latter, vascular endotheliocytes, alveolar epithelium (type II pneumocytes) can take part [16].

One of the factors triggering the endothelial-mesenchymal and epithelial-mesenchymal transformation can be hypoxemia [17].

Some scientists note the role of CD44 and metalloproteinase-9 in the development of pneumosclerosis after COVID-19. CD44 with hyaluronic acid activates the Phosphatidylinositol 3 Kinase/Protein Kinase B pathway, which induces the reduction in cellular apoptosis, increasing the survival of fibroblasts and myofibroblasts. Metalloproteinase-9 is expressed by alveolar epithelial cells, neutrophils, macrophages, and fibroblasts being able to activate TGF- β 1, which contributes to the increase in the active TGF- β pool [18].

The infiltration by immune cells revealed by the authors in the foci of pneumosclerosis, which increased in parallel with sclerotic changes, indicates the participation of these cells in the development of pneumosclerosis.

In the foci of pneumosclerosis, the authors identified dystrophic calcification in 17 cases of groups 1-3, which is due to ongoing physicochemical changes in tissues, followed by the absorption of calcium salts from the blood and tissue fluid [19]. Also, in the areas of pneumosclerosis in 23 cases of groups 1-3, metaplasia of the connective tissue was noted with the formation of adipose, bone and cartilage tissues. In this case, before




Fig. 8. The average values of the specific volumes of unchanged alveoli, alveoli with emphysematous and atelectatic changes in the lungs in groups 1-3.




Fig. 9. Hemodynamic changes in the lungs in groups 2 (a) and 3 (b). Stained with hematoxylin and eosin, a) $\times 100$, b) $\times 200$.

the formation of adipose, bone, and cartilage tissues, proliferation of young cells of the connective tissue was noted, followed by differentiation into adipocytes, chondrocytes, and osteocytes. The changes in the connective tissue identified by the authors did not depend on the severity of the infection.

The sclerotic changes in the lungs identified by the authors led to a decrease of the parenchymal component, and with an increase of the severity of the infection, this pattern increased, which, accordingly, would lead to an increase the respiratory failure signs.

In all cases of groups 1-3, hemodynamic disorders were detected which depended on the severity of the infection and were characterized by edema, vascular plethora, thrombosis, small-focal hemorrhages with hemosiderin deposition. Similar changes have been described by scientists in the lungs during COVID-19 [20, 21].

Many scientists use the term COVID-19-associated interstitial lung disease (ILD) to describe pneumosclerosis as an outcome of COVID-19. Some scientists describe pulmonary aspergillosis as a manifestation of respiratory disorders of post-COVID-19 syndrome [22]. In our study, pulmonary aspergillosis was not detected. In our previous studies, we described chronic atrophic rhinosinusitis in patients in post-COVID-19 period caused by the association of bacteria and fungi. Among fungi, there were *Aspergillus*, *Candida*, *Mucor* and *Coccidioides* [23].

Sclerotic changes in the lungs were combined with damage of the parenchymal component. Damage of the latter was characterized, firstly, by focal degenerative-desquamative changes of the alveolar epithelium, which, together with the above described sclerotic changes of the basement membranes, leads to a violation of the morphofunctional state of the air-blood barrier and the development of parenchymal

respiratory failure. Secondly, changes of the parenchymal component were characterized by a decrease of the specific volume of unchanged alveoli and an increase of the specific volume of emphysematous and atelectatically changed alveoli. The authors found an increase of these changes with increasing severity of COVID-19.

Also, changes of the parenchymal component of the lungs were characterized by damage of the epithelial layer of the bronchial tree, deformed due to sclerosis. In all cases of groups 1-3 the authors noted dystrophic changes. In 20 cases of groups 1-3 metaplastic and dysplastic changes sometimes with the formation of adenomatous structures were detected in the epithelial layer of the deformed bronchial tree. The changes in the bronchial epithelium identified by the authors did not depend on the severity of COVID-19.

Metaplasia and dysplasia are precancerous conditions [24, 25]. Therefore, the dysplastic and metaplastic changes identified by the authors in the epithelial layer of the bronchial tree, which did not depend on the severity of COVID-19, indicate that these patients are more likely to develop lung cancer in the future. It's just a hypothesis that requires years of research.

Some scientists in their studies also suggest that COVID-19 may be a risk factor for lung cancer [26].

There are studies in the literature that found that pneumosclerosis, immune cells infiltration, dysplastic and metaplastic changes in the epithelium of the bronchi are the basis for the development of peripheral lung cancer ("cancer in the scar") [27]. There are epigenetic and genetic alterations, abnormal expression of microRNAs, cellular and molecular aberrances such as an altered response to regulatory signals, delayed apoptosis or reduced cell-to-cell communication, along with the activation of specific signaling transduction

pathways, all these characterize the pathogenesis of pneumosclerosis and lung cancer [27].

Sadigov A. et al. showed in their studies that lung cancer most common was found at three months after lung infection, and most commonly incidence of lung cancer was observed in patients after surviving severe COVID-19 infection with severe acute respiratory distress syndrome in whom was developed massive and non-resolving fibrosis with history of cigarette smoking and most commonly type of the lung cancer was squamous cell lung cancer [28].

CONCLUSIONS

1. Morphological features of the lungs in post-COVID-19 syndrome are the presence of pneumosclerosis; focal-diffuse immune cells infiltration; emphysematous and atelectatic changes; degenerative-desquamatic changes in the alveolar epithelium; metaplastic changes

of connective tissue; dystrophic calcification; dystrophic, metaplastic and dysplastic changes in the epithelial layer of bronchial tree; hemodynamic disorders.

2. Pneumosclerosis, focal-diffuse immune cells infiltration, alterative changes in the alveolar epithelium, emphysematous and atelectatic changes, hemodynamic disorders increased with an increase the severity of COVID-19. Metaplastic changes of connective tissue, dystrophic calcification, dystrophic, metaplastic and dysplastic changes in the epithelial layer of bronchial tree did not depend on the severity of the infection.
3. The changes identified by the authors help to explain pulmonary manifestations of post-COVID-19 syndrome. They should be the basis for the oncological alertness formation among doctors, the development of rehabilitation and treatment measures for such category of patients.

REFERENCES

1. Montani D, Savale L, Noel N, et al. COMEBAC Study Group. Post-acute COVID-19 syndrome. *Eur Respir Rev.* 2022;31(163):210185.
2. Oronsky B, Larson C, Hammond TC, et al. A review of persistent post-COVID syndrome (PPCS). *Clin Rev Allergy Immunol.* 2023;64(1):66-74.
3. Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: an overview. *Diabetes Metab Syndr.* 2021;15(3):869-875.
4. Soriano JB, Murthy S, Marshall JC, et al. WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. *Lancet Infect Dis.* 2022;22(4):e102-e107.
5. Yan MZ, Yang M, Lai CL. Post-COVID-19 syndrome comprehensive assessment: from clinical diagnosis to imaging and biochemical-guided diagnosis and management. *Viruses.* 2023;15(2):533.
6. Raman B, Bluemke DA, Lüscher TF, Neubauer S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. *Eur Heart J.* 2022;43(11):1157-1172.
7. Pierce JD, Shen Q, Cintron SA, Hiebert JB. Post-COVID-19 syndrome. *Nurs Res.* 2022;71(2):164-174.
8. Visco V, Vitale C, Rispoli A, et al. Post-COVID-19 syndrome: involvement and interactions between respiratory, cardiovascular and nervous Systems. *J Clin Med.* 2022;11(3):524.
9. Antoniou KM, Vasarmidi E, Russell AM, et al. European Respiratory Society statement on long COVID follow-up. *Eur Respir J.* 2022;60(2):2102174.
10. Fernández-Plata R, Higuera-Iglesias AL, Torres-Espíndola LM, et al. Risk of pulmonary fibrosis and persistent symptoms post-COVID-19 in a cohort of outpatient health workers. *Viruses.* 2022;14(9):1843.
11. Esendağlı D, Yılmaz A, Akçay Ş, Özlü T. Post-COVID syndrome: pulmonary complications. *Turk J Med Sci.* 2021;51(SI-1):3359-3371.
12. Song WJ, Hui KKM, Hull JH, et al. Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses. *Lancet Respir Med.* 2021;9(5):533-544.
13. Myroshnychenko M, Sukhorukov I, Dyadyk O, et al. Morphological features of the lungs in post-COVID-19 period. *Medicina (Kaunas).* 2023;59(Supplement 1):43.
14. Rai DK, Sharma P, Kumar R. Post-COVID-19 pulmonary fibrosis. Is it real threat? *Indian J Tuberc.* 2021;68(3):330-333.
15. Hama Amin BJ, Kakamad FH, Ahmed GS, et al. Post COVID-19 pulmonary fibrosis; a meta-analysis study. *Ann Med Surg (Lond).* 2022;77:103590.
16. Eapen MS, Lu W, Gaikwad AV, et al. Endothelial to mesenchymal transition: a precursor to post-COVID-19 interstitial pulmonary fibrosis and vascular obliteration? *Eur Respir J.* 2020;56(4):2003167.
17. Vishnupriya M, Naveenkumar M, Manjima K, et al. Post-COVID pulmonary fibrosis: therapeutic efficacy using with mesenchymal stem cells – How the lung heals. *Eur Rev Med Pharmacol Sci.* 2021;25(6):2748-2751.
18. Vaz de Paula CB, Nagashima S, Liberalesso V, et al. COVID-19: immunohistochemical analysis of TGF- β signaling pathways in pulmonary fibrosis. *Int J Mol Sci.* 2021;23(1):168.
19. KazymyrkoVK, Silantieva TS, Ivanitska LN, et al. Calcification of arteries in patients with atherosclerosis: causes and mechanisms of development. *Likars'ka Sprava.* 2021;3-4:17-35.

20. Sastry S, Cuomo F, Muthusamy J. COVID-19 and thrombosis: the role of hemodynamics. *Thromb Res.* 2022;212:51-57.
21. Gencer S, Lacy M, Atzler D, et al. Immunoinflammatory, thrombohaemostatic, and cardiovascular mechanisms in COVID-19. *Thromb Haemost.* 2020;120(12):1629-1641.
22. Zubairi ABS, Shaikh A, Zubair SM, et al. Persistence of post-COVID lung parenchymal abnormalities during the three-month follow-up. *Adv Respir Med.* 2021;89(5):477-483.
23. Myroshnychenko MS, Kalashnyk-Vakulenko YM, Kapustnyk NV, et al. Rhinosinusitis in patients in post-COVID-19 period: etiology, clinical and morphological characteristics. *Wiad Lek.* 2022;75(8 pt 2):1945-1953.
24. Giroux V, Rustgi AK. Metaplasia: tissue injury adaptation and a precursor to the dysplasia-cancer sequence. *Nat Rev Cancer.* 2017;17(10):594-604.
25. Thébaud B, Goss KN, Laughon M, et al. Bronchopulmonary dysplasia. *Nat Rev Dis Primers.* 2019;5(1):78.
26. Tao SL, Wang XM, Feng YG, et al. Is the presence of lung injury in COVID-19 an independent risk factor for secondary lung cancer? *Med Hypotheses.* 2020;143:110074.
27. Sapalidis K, Sardeli C, Pavlidis E, et al. Scar tissue to lung cancer; pathways and treatment. *J Cancer.* 2019;10(4):810-818.
28. Sadigov A, Akhundov S, Agayeva A. Risk factors for lung cancer in individuals with COVID-19 without cancer history. *Respiratory Care.* 2021;66 (Suppl. 10):3566906.

ORCID and contributionship:

Mykhailo S. Myroshnychenko: 0000-0002-6920-8374^D

Nana M. Pasiyeshvili: 0000-0002-8016-4288^E

Nataliia V. Kapustnyk: 0000-0002-4875-398X^A

Volodymyr D. Markovskiy: 0000-0002-2237-3639^F

Yuliia M. Kalashnyk-Vakulenko: 0000-0002-7733-3503^B

Olga V. Zaytseva: 0000-0002-0330-1568^C

Maryna A. Bondarenko: 0000-0002-0203-0161^C

Oleksandr V. Morozov: 0000-0002-4354-7829^E

Dmytro V. Molodan: 0000-0002-7679-8288^F

Conflict of interest:

The Authors declare no conflict of interest

CORRESPONDING AUTHOR**Mykhailo S. Myroshnychenko**

D.O. Alpern Department of General and Clinical Pathophysiology

Kharkiv National Medical University

Str. Svetlaya27A, apt. 70, 61129, Kharkiv, Ukraine

tel: +380501699763, +380961033038

e-mail: msmartyroshnychenko@ukr.net

Received: 12.10.2022

Accepted: 27.04.2023

A – Work concept and design, B – Data collection and analysis, C – Responsibility for statistical analysis, D – Writing the article, E – Critical review, F – Final approval of the article

 Article published on-line and available in open access are published under Creative Common Attribution-Non Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0)